Crispr Therapeutics AG (CRSP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.10B
Last updated: Nov 17, 2026 at 11:05 AM ET
Crispr Therapeutics AG (CRSP) Stock Forecast
Analysts expect Crispr Therapeutics AG (CRSP) to earn -$4.53 per share in the fiscal year ending Dec 31, 2026, on revenue of $35.49M. Of 23 analysts, 13 rate the stock Buy or Strong Buy, 10 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 6 estimates for the fiscal year ending Dec 31, 2026 were revised up and 9 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 23 ratings average 2.26, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 57% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 4 | 17.4% |
| Buy | 9 | 39.1% |
| Hold | 10 | 43.5% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 23
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 277.8%.
- Fiscal year ending Dec 31, 2026
- -$4.53
- EPS consensus, revenue $35.49M
- Fiscal year ending Dec 31, 2027
- -$3.69
- EPS consensus, revenue $134.07M
- Next report
- Feb 10, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$4.53 | -$4.99 to -$4.12 | 19 | $35.49M | $12.33M to $80.89M | 19 |
| Dec 31, 2027 | -$3.69 | -$5.34 to -$0.42 | 20 | $134.07M | $1.00M to $509.00M | 18 |
Quarterly Estimates
The EPS consensus rises from -$1.26 for the quarter ending Dec 31, 2026 to -$1.09 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.26 | -$2.10 to -$0.79 | 22 | $9.87M | N/A | 21 |
| Mar 31, 2027 | -$1.09 | -$1.33 to -$0.73 | 7 | $11.45M | $300000 to $42.55M | 7 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 13 upward and 16 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 6 | 9 |
| Fiscal year ending Dec 31, 2027 | 3 | 6 |
| Quarter ending Mar 31, 2027 | 4 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$4.48.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$4.53 | -$4.49 | -$4.45 | -$4.45 | -$4.48 | N/A |
| Fiscal year ending Dec 31, 2027 | -$3.69 | -$3.75 | -$3.52 | -$3.50 | -$3.51 | N/A |
| Quarter ending Mar 31, 2027 | -$1.09 | -$1.09 | -$0.89 | -$0.89 | -$0.89 | N/A |
Frequently Asked Questions About CRSP
What is the CRSP stock forecast?
Consensus analyst estimates put Crispr Therapeutics AG's EPS at -$4.53 for the fiscal year ending Dec 31, 2026, on revenue of $35.49M. The consensus rating from 23 analysts is Buy.
How do analysts rate CRSP stock?
Of 23 analysts covering Crispr Therapeutics AG, 4 rate it Strong Buy, 9 Buy, 10 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from CRSP next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$4.53, with estimates from -$4.99 to -$4.12 from 19 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$3.69, with estimates from -$5.34 to -$0.42 from 20 analysts.
What revenue do analysts expect from Crispr Therapeutics AG next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $35.49M, with estimates from $12.33M to $80.89M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $134.07M, with estimates from $1.00M to $509.00M.
How many analysts cover CRSP?
23 analysts rate Crispr Therapeutics AG stock, and 19 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
CRSP pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors